MASLD and MASH
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Formerly known as nonalcoholic fatty liver disease (NAFLD), MASLD is often a silent condition where the liver becomes infiltrated with fat (steatosis), causing dysfunction at a cellular level. Affected individuals may go on to develop inflammation, leading to MASH described below.
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Formerly known as non-alcoholic steatohepatitis (NASH), MASH is defined as the presence of hepatic steatosis and inflammation, with or without fibrosis or scarring. MASH is a progressive condition and without intervention can lead to cirrhosis, liver cancer, and ultimately to liver failure.
MASH PATIENTS TYPICALLY DO NOT SHOW SYMPTOMS
Non-invasive tests can be performed to assess a patient for potential MASH
Fibrosis Scores
FIB-4, ELF and
other lab based tests.
Currently, there are limited FDA approved therapies to treat MASH. Several clinical research studies for developing treatments are available.
Contact DRI today to schedule a no-cost FibroScan® and see if a clinical trial is right for you.
AM I AT RISK?
The largest risk factors are Type 2 Diabetes and Obesity. Risk also increases with age, menopause, and conditions within the metabolic syndrome.
STAGES OF LIVER DISEASE
RISK FACTORS
Can you identify with any of these conditions that put you at an elevated risk of having or developing liver disease?
Diabetes
Abnormal Cholesterol
High Triglycerides,
Low HDL, High LDL
Overweight
BMI Over 25
Post-Menopause
Alcohol Consumption
and Tobacco Use
High Blood Pressure
Over 130/80 mmHg
